Corporate Whistleblower Center Now Urges Drug Company Insiders With Proof Of Off Labeling To Call Them About Reward Because Of A Recent Settlement Involving Risperdal

• 

We believe off labeling pharmaceutical marketing schemes are so wide spread it would almost be impossible to comprehend

(PRWEB) April 14, 2014

The Corporate Whistleblower Center says, "We believe off labeling pharmaceutical marketing schemes are so wide spread it would almost be impossible to comprehend. Additionally, we are convinced pharmaceutical reps, managers, or even medical doctors could cash in big with a huge whistleblower reward for this type of information. The only caveats are, the potential whistleblower must possess well documented proof of the wrongdoing, and the amount of Medicare overbilling must exceed one million dollars." For more information, potential whistleblowers are encouraged to contact the Corporate Whistleblower Center anytime at 866-714-6466.

In a recent example of off labeling, according to a November 2013 Justice Department press release Global health care giant Johnson & Johnson (J&J) and its subsidiaries will pay more than $2.2 billion to resolve criminal and civil liability arising from allegations relating to the prescription drugs Risperdal, Invega and Natrecor, including promotion for uses not approved as safe and effective by the Food and Drug Administration (FDA). Additionally, there were alleged payment of kickbacks to physicians and to the nation’s largest long-term care pharmacy provider. The global resolution is one of the largest health care fraud settlements in U.S. history, including criminal fines and forfeiture totaling $485 million, and civil settlements with the federal government and states totaling $1.72 billion.

The United States alleges that Janssen marketed Risperdal to control the behaviors and conduct of the nation’s most vulnerable patients: elderly nursing home residents, along with children and individuals with mental disabilities. The government alleges that J&J and Janssen caused false claims to be submitted to federal health care programs by promoting Risperdal for off label uses that federal health care programs did not cover. The company also allegedly made false and misleading statements about the safety as well as efficiency of Risperdal. Allegedly the company was also involved in paying kickbacks to physicians to prescribe Risperdal. http://CorporateWhistleblowerCenter.Com

Simple rules for a whistleblower from the Corporate Whistleblower Center:

• Do not go to the government first if you are a major whistleblower. The Corporate Whistleblower Center says, “Major whistleblowers frequently go to the federal government thinking they will help. It’s a huge mistake.”
• Do not go to the news media with your whistleblower information. Public revelation of a whistleblower’s information could destroy any prospect for a reward.
• Do not try to force a government contractor, or corporation to come clean to the government about their wrongdoing. The Corporate Whistleblower Center says, “Fraud is so rampant among federal contractors that any suggestion of exposure might result in an instant job termination, or harassment of the whistleblower. Come to us first, tell us what type of information you have, and if we think it’s sufficient, we will help find the right law firms to assist in advancing your information.”
• The Corporate Whistleblower Center wants to emphasize there are high quality whistleblowers in every state including California, New York, Florida, Texas, Massachusetts, Maryland, Virginia, Ohio, Pennsylvania, West Virginia, Tennessee, North Carolina, Georgia, Alabama, Louisiana,     Missouri, Michigan, Iowa, Indiana, Illinois, Wisconsin, Minnesota, North     Dakota, South Dakota, Montana, Wyoming, Nebraska, Kansas, Colorado, Utah, New Mexico, Arizona, Nevada, Idaho, Oregon, Washington, and Alaska.

Any type of insider or employee who possesses significant proof of their employer or a government contractor defrauding the federal government is encouraged to contact to Corporate Whistleblower Center anytime at 866-714-6466 or via their web site at http://CorporateWhistleBlowerCenter.Com

For attribution purposes please refer to the November 2013 Department of Justice Press release on this matter: http://www.justice.gov/opa/pr/2013/November/13-ag-1170.html

Case number: Skala V. Johnson & Johnson ed al. Docket No. LDL-L6820-06 New Jersey Superior Court.

PDF Print